DNMT3B and acute myeloid leukemia: Secondly, while analysis of the Flt3-ITD negative patients included in the analysis of Verhaak et al [36] showed a strong trend for decreased survival of DNMT3B high-expressing AML patients (p = 0.05 each for event-free and overall survival), this was not the case for FLT3-ITD positive patients (not shown).